
Perspective Therapeutics
Perspective Therapeutics: A global biotech startup innovating cancer treatment with proprietary radiation technology.

Perspective Therapeutics: A global biotech startup innovating cancer treatment with proprietary radiation technology.
Perspective Therapeutics, founded with a mission to revolutionize cancer treatment, is a biotech company that specializes in innovative radiation therapies. The company's core vision is to develop game-changing therapies that significantly improve outcomes for cancer patients. Their primary products include cesium-131 brachytherapy seeds and a proprietary technology utilizing the isotope lead-212, which delivers targeted alpha radiation to cancer cells. Perspective Therapeutics focuses on theranostics, a field that combines diagnostic imaging and targeted therapy to enhance treatment efficacy and reduce toxicity.
Notable figures associated with Perspective Therapeutics include leading oncologists and researchers who contribute to the development of their cutting-edge technologies. The company has attracted significant investment from venture capital firms specializing in biotech innovations. Key achievements include the successful development and deployment of their cesium-131 brachytherapy seeds and lead-212-based therapies, which have shown promising results in clinical trials. Overall, Perspective Therapeutics has made a substantial impact on the field of oncology by providing more precise and effective treatment options for cancer patients worldwide.
Companies similar to Perspective Therapeutics include PanTher Therapeutics, PNP Therapeutics, Radionetics Oncology and PIC Therapeutics.
Perspective Therapeutics was founded in 2018.
Perspective Therapeutics' headquarters is located in Richland, WA, US.
Perspective Therapeutics' most recent funding round was for $400k (USD) in February 2024.
As of Feb 1, 2024, Perspective Therapeutics has disclosed funding of $90.2M (USD). Undisclosed round amounts are excluded.
Perspective Therapeutics has 66 employees as of Feb 5, 2024.

PanTher Therapeutics
panthertx.com

PNP Therapeutics

Radionetics Oncology
radionetics.com

PIC Therapeutics

Perthera
perthera.com

Palm Therapeutics

A2 Biotherapeutics
a2bio.com

Window Therapeutics
windowtx.com

PineTree Therapeutics
pinetreetx.com

Parthenon Therapeutics
parthenontx.com

Partner Therapeutics
partnertx.com

Kestrel Therapeutics

Dialectic Therapeutics
dtsciences.com

Perscitus Biosciences

Starton Therapeutics